Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 512
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMG 512 (also known as CDH19 BiTE) is a bispecific T-cell engager (BiTE) antibody construct developed by Amgen for the treatment of melanoma. It is designed to simultaneously bind to cadherin-19 (CDH19), an unconventional type 2 cadherin highly expressed in melanoma, and the CD3 epsilon subunit of the T-cell receptor complex. By bridging these two targets, AMG 512 redirects the cytotoxic activity of T cells to specifically eliminate CDH19-expressing melanoma cells. The molecule is a half-life extended (HLE) BiTE, incorporating an Fc domain to prolong its circulatory presence. Preclinical data indicated potent anti-tumor activity, including against cells resistant to BRAF/MEK inhibitors and checkpoint inhibitors. Clinical development was halted following a Phase 1 study.
- Other names
- CDH19 BiTECDH-19 BiTECDH 19 BiTEanti-CDH19/CD3 HLE BiTECDH19-CD3 BiTECDH-19-CD3 BiTECDH 19-CD3 BiTECDH19-CD3 bispecific T-cell engagerCDH-19-CD3 bispecific T-cell engagerCDH 19-CD3 bispecific T-cell engager
02
Targets
CD3 (T-cell surface glycoprotein CD3)CDH19 (Cadherin-19)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on AMG 512.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 512.